Santen's basic R&D strategy is to commercialize new drugs quickly. To achieve this, it concentrates management resources on promising projects in fields where the company can display its strengths, thus raising its value as a unique pharmaceutical company. In its core field of ophthalmology, Santen focuses on original discovery research as well as research that applies compounds developed as general drugs, such as anti-infective agents, to the field of ophthalmology. Key targets are creating next-generation ophthalmic drugs and strengthening research in the retinal field.
Generating research results efficiently and quickly is essential. Santen therefore has created a research organization that clarifies initiatives and responsibilities by allocating ophthalmic researchers mainly in groups specializing in glaucoma, inflammatory and corneal disorders, and retinal disorders.
Santen has a close cooperation with the universities and research institutes within the field of ophthalmology. Close communication with medical doctors, who are on the front lines of healthcare, supports Santen's ability to develop pharmaceuticals from the perspective of patients. Leveraging the results of leading-edge ophthalmological research, Santen develops pharmaceutical treatments that meet the needs of patients and healthcare practitioners.
